Two cases of death resulting from gene editing experiments on children have been exposed within half a month, and industry insiders warn that the pursuit of global innovation must not overlook clinical safety and compliance requirements.

Following the exposure of the death of a 6-year-old girl in late July after undergoing the "world's first brain gene editing" treatment, on August 5, a Shanghai-based gene therapy company, Huida Gene, disclosed a statement regarding the situation. It reported that in August 2025, during the first human clinical trial for Duchenne muscular dystrophy, a participant in the high-dose group unfortunately passed away after receiving the HG302 treatment. The cause of death was attributed to "acute respiratory distress syndrome occurring against the background of severe activation of complement and cytokines following high-dose systemic administration of an adeno-associated virus vector." In just half a month, two incidents of child deaths in 2025 have come to light, both pointing to the potential risks of rushing for "global innovation" in clinical trials initiated by researchers. Multiple experts in the field have indicated that these unfortunate events reveal issues such as overly rapid progression, insufficient risk recognition, and lack of compliance in some domestic IIT trials.